… ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology Key updates ProQR presents in vivo data in a relevant disease model, … The Netherlands, Sept. 21, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), today announced that a …
… ProQR Announces Results for the Third Quarter of 2015 and … LEIDEN, The Netherlands, Nov. 23, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … studies," said Daniel de Boer, Chief Executive Officer of ProQR. “Our teams have taken a number of steps to accelerate …
… ProQR Provides Enrollment Update on QR-110 Clinical Trial and … and retinal structure in the second half of the year. ProQR to present two abstracts on programs for Fuchs … said Daniel A. de Boer, Chief Executive Officer of ProQR. “We look forward to the clinical data for the QR-110 …
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced that Company management will pres
… ProQR to Participate in a Cystic Fibrosis Panel Discussion … LEIDEN, The Netherlands, June 13, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that … being held at The St. Regis in New York, NY, USA. About ProQRProQR Therapeutics is dedicated to changing lives …
… ProQR Announces Publication in Nature Medicine of QR-110 Data … and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … is expected to start in the first half of 2019. About ProQRProQR Therapeutics is dedicated to changing lives …
… ProQR spins out Amylon Therapeutics as a privately-held … on central nervous system (CNS) therapeutics Key updates ProQR spins out CNS-focused company, Amylon Therapeutics, … and private investors. As part of the transaction, ProQR has granted an exclusive license to Amylon to develop …
… ProQR Prices Approximately $20 Million Underwritten Public … LEIDEN, The Netherlands, Nov. 14, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical … $3.25 per share. All of the shares are being offered by ProQR. In addition, in the public offering, ProQR has …